Medtech firm Mainstay gathers €25m war chest to chase FDA
The cash call is double the figure it had set itself earlier this year as it begins a push for US drug regulators to sign off on its back pain treatment next year
Medical device maker Mainstay has raised almost €17 million in cash from investors as it attempts to secure approval for its chronic back pain treatment.
The cash call is double the figure it had set itself earlier this year as it begins a push for US drug regulators to sign off on its treatment next year. The fundraising will also allow it to draw down a further €3 million loan.
The money is being provided by a...
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply